By stimulating human patient-derived tumor cells (T-TEC) in vitro with a mutant, non-iron-binding Lcn-2, the iron-binding capacity was disabled in comparison to normal non-modified protein, resulting in a significant reduction in the intracellular iron amount. The gene discussed is LCN2; the disease is neoplasm.